Skip to content

Construction of a diagnostic model of irritable bowel syndrome based on intestinal flora and clinical study of Chinese herbal medicine compound treatment

Construction of a diagnostic model of irritable bowel syndrome based on intestinal flora and clinical study of Chinese herbal medicine compound treatment

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000794
Enrollment
Unknown
Registered
2025-04-21
Start date
2023-05-01
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Irritable bowel syndrome

Interventions

IBS-D (control group):Administer placebo granules for treatment
IBS-C (control group):Administer placebo granules for treatment
IBS-D (experimental group):Administer Xifenghuashi granules for treatment
IBS-C (experimental group):Administer Traditional Chinese Medicine Yunpi Rougan Granules

Sponsors

Jiangsu Provincial Hospital of Integrative Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Meets the diagnostic criteria of IBS-D and IBS-C in both traditional Chinese and Western medicine; (2) Age range of 18-70 years old gender not limited; (3) Informed consent and voluntary participation in research.

Exclusion criteria

Exclusion criteria: (1) Individuals with organic lesions in the gastrointestinal tract; (2) Individuals with severe heart liver kidney respiratory blood and endocrine disorders; (3) Patients with mental illness and severe neurological disorders; (4) Pregnant or lactating women; (5) Individuals with poor adherence to medical orders and allergies to this medication; (6) Patients who have participated in clinical studies of other drugs within the past 3 months or are currently enrolled; (7) Alcoholic and drug abusers and drug addicts *; (8) Individuals who have taken antibiotics probiotic preparations or gastrointestinal motility promoting drugs within one month prior to inclusion in the trial. *Alcohol abuse standard: Men should drink more than 50 grams of alcohol per day and women should drink more than 30 grams of alcohol per day; Drug use is judged based on clinical symptoms.

Design outcomes

Primary

MeasureTime frame
Evaluation of overall clinical efficacy;

Secondary

MeasureTime frame
Criteria for assessing symptom severity;Quality of life assessment criteria;Grading criteria for TCM syndromes;Psychological status assessment criteria;Fecal 16s rRNA gene sequencing;

Countries

CHINA

Contacts

Public ContactHUI LI

Jiangsu Provincial Hospital of Integrative Medicine

32260890@qq.com17601558686

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026